GenoMed, Inc. Brings in First Patient Revenues
ST. LOUIS, December 11, 2002 GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics company, announced today that it has collected its first patient revenues.
Dr. Moskowitz commented, "We are very pleased to report our first revenues from patients enrolling in our Clinical Outcomes Improvement Program (TM). One of the patients, in particular, has been under no treatment, but has borderline hypertension and a family history positive for type 2 diabetes. This is early enough in the course of disease to hope for prevention of diabetes altogether."
Dr. Moskowitz continued, "We look forward to a long and mutually beneficial relationship with these patients. Time will tell whether our novel treatment, which we know to be safe, will be able to protect these patients against more than diabetes and cardiovascular disease, for example, against common cancers. We look forward to trying to stay healthy and growing old together."
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article
Business Journal Story
reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use.
Consistent with the Company's goal to improve patient outcomes globally, GenoMed is currently working to license its treatments to physicians and patients worldwide.
For questions or appointments, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com. |
